Harvey Investment Co. LLC Has $29.17 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Harvey Investment Co. LLC cut its position in Agilent Technologies, Inc. (NYSE:A) by 1.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 217,132 shares of the medical research company’s stock after selling 2,150 shares during the quarter. Agilent Technologies comprises 3.4% of Harvey Investment Co. LLC’s holdings, making the stock its 9th biggest position. Harvey Investment Co. LLC’s holdings in Agilent Technologies were worth $29,170,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of A. CKW Financial Group raised its holdings in shares of Agilent Technologies by 114.9% during the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock valued at $25,000 after buying an additional 100 shares during the last quarter. Global X Japan Co. Ltd. increased its position in Agilent Technologies by 161.1% in the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 116 shares during the period. Livelsberger Financial Advisory bought a new stake in Agilent Technologies during the 3rd quarter valued at $28,000. Ashton Thomas Securities LLC bought a new stake in Agilent Technologies during the 3rd quarter valued at $31,000. Finally, Fortitude Family Office LLC boosted its position in Agilent Technologies by 68.3% during the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock worth $35,000 after acquiring an additional 95 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Company cut their price objective on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a research note on Monday, December 9th. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Barclays decreased their price objective on shares of Agilent Technologies from $145.00 to $135.00 and set an “underweight” rating for the company in a report on Wednesday, November 27th. Bank of America dropped their target price on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Finally, Citigroup increased their price target on Agilent Technologies to $165.00 and gave the company a “buy” rating in a research note on Thursday, December 19th. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $143.62.

Insider Buying and Selling

In related news, CEO Padraig Mcdonnell sold 1,911 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. This represents a 4.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Agilent Technologies Stock Performance

Shares of NYSE A opened at $147.66 on Friday. Agilent Technologies, Inc. has a 52-week low of $124.16 and a 52-week high of $155.35. The stock has a market capitalization of $42.17 billion, a price-to-earnings ratio of 33.41, a PEG ratio of 4.10 and a beta of 1.07. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57. The stock’s fifty day simple moving average is $141.44 and its 200 day simple moving average is $139.19.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The firm had revenue of $1.70 billion for the quarter, compared to analysts’ expectations of $1.67 billion. During the same quarter last year, the business posted $1.38 EPS. Agilent Technologies’s revenue was up .8% on a year-over-year basis. As a group, sell-side analysts forecast that Agilent Technologies, Inc. will post 5.56 earnings per share for the current fiscal year.

Agilent Technologies Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st were paid a $0.248 dividend. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Tuesday, December 31st. This represents a $0.99 dividend on an annualized basis and a yield of 0.67%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.40%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.